Retarded Or Controlled-release Layer Produced (e.g., Enteric) Patents (Class 427/2.21)
-
Patent number: 8822489Abstract: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.Type: GrantFiled: February 27, 2013Date of Patent: September 2, 2014Assignee: Acura PharmaceuticalsInventors: Vijai Kumar, David Dixon, Divya Tewari, Dilip B. Wadgaonkar
-
Publication number: 20140242168Abstract: The present invention provides perorally administrable drug release systems and processes for producing perorally administrable systems having a drug-containing core and a sheath which surrounds the core and comprises a swellable shell and an elastic coating which surrounds at least the shell, the sheath having at least one orifice.Type: ApplicationFiled: July 6, 2012Publication date: August 28, 2014Applicant: LTS LOHMANN THERAPIE-SYSTEME AGInventors: Christiane Schiller, Knut Seidlitz
-
Publication number: 20140242162Abstract: The invention relates to extended release pharmaceutical formulations in form of multiparticulates comprising 40-O-(2-hydroxy)ethyl-rapamycin, to dosage forms which comprise said pharmaceutical formulations, to methods of preparing said pharmaceutical formulations and said dosage forms, to uses of said pharmaceutical formulations and said dosage for the manufacture of a medicament for the treatment or prevention of diseases or conditions responsive to inhibition of mTOR signaling pathway, such as for instance proliferative diseases or immunosuppression.Type: ApplicationFiled: October 3, 2012Publication date: August 28, 2014Inventors: Anke Diederich, Kurt Liechti, Peter Kuehl, Wing Cheung
-
Publication number: 20140228747Abstract: Disclosed is a bolus comprising: a bolus body comprising a matrix material and one or more biologically beneficial substances contained in and/or on the matrix; wherein the exterior surface of the bolus body is shaped so as to have a least one recessed portion; and at least part of the recessed portion of the bolus body is coated with a material which retards or inhibits release of the beneficial substance(s) from the matrix.Type: ApplicationFiled: June 10, 2013Publication date: August 14, 2014Applicant: ANIMAX LTDInventor: William Leslie Porter
-
Publication number: 20140227351Abstract: Taste masked multi-layered particles include an inert core, one or more coating layer(s) comprising a pharmaceutically active ingredient and a binder, an intermediate coating layer (seal coating) free from a low molecular weight water-soluble ionic compound and including a water-soluble pharmaceutical film-forming compound selected from (i) HPMC and PEG or (ii) PVP, and an outer coating layer (final or taste masking coating) free from a low molecular weight water-soluble ionic compound and comprising (i) a poly(meth)acrylate or (ii) a mixture including 60-90% (w/w) EC and 10-40% (w/w) HPMC, where the pharmaceutically active ingredient is water-soluble and includes either at least one basic group and/or a bitter taste. Further disclosed are methods for the production of such particles and pharmaceutical compositions including such particles.Type: ApplicationFiled: April 16, 2014Publication date: August 14, 2014Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Martin FOLGER, Stefan LEHNER, Annette GRAVE, Norbet POELLINGER, Randolph SEIDLER
-
Patent number: 8802184Abstract: A method of modifying a medical device such as a stent with nano-constructs is disclosed. The method comprises applying a first fluid to the stent; immersing the stent being wet from the first fluid into a second fluid having a suspension of nano-constructs; and removing the stent from the second fluid and allowing the first and second fluid to be removed such that the nano-constructs are carried by the stent for in vivo application of the constructs to a target location of a mammalian subject. The nano-constructs can be attached to the surface of the stent, can be attached to a surface of the coating of the stent, can be embedded into the stent, or can be embedded into the coating.Type: GrantFiled: May 30, 2007Date of Patent: August 12, 2014Assignee: Abbott Cardiovascular Systems Inc.Inventors: Syed F. A. Hossainy, Dariush Davalian, Jinping Wan, Troy Carter, Charles Silvis
-
Publication number: 20140199469Abstract: A method for producing a sustained-release tablet having improved stability and content uniformity is provided. The method involves first preparing a core tablet by granulating, drying, milling, blending, and compressing a mixture of active and inactive ingredients. Four coating layers are applied to the core tablet: an inner layer, an enteric coating layer, an active layer, and an outer layer. The active ingredient may be a tetracycline, such as doxycycline. A sustained-release tablet prepared according to the method is also described.Type: ApplicationFiled: February 25, 2014Publication date: July 17, 2014Applicant: Galderma S.A.Inventors: Sandrine SEGURA, Ludovic BUSSARD, Jean-Pierre ETCHEGARAY
-
Publication number: 20140186515Abstract: Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing full access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any penetration of the immediate-release drug into the prolonged-release portion.Type: ApplicationFiled: March 6, 2014Publication date: July 3, 2014Applicant: DEPOMED, INC.Inventors: Jong Lim, John N. Shell, Jenny Louie-Helm
-
Publication number: 20140187497Abstract: A method of forming an ocular delivery device includes exposing a solid, shaped cellulose polymer to a solution including an active pharmaceutical ingredient (API) and a solvent capable of solubilizing the API, wherein the polymer absorbs at least a portion of the solution, including the API and solvent. The method may further include removing at least a portion of the absorbed solvent from the polymer by allowing the absorbed solvent to evaporate from the polymer or by drying the polymer. A variety of cellulose polymers may be used, including hydroxypropyl cellulose. A variety of APIs may be used, including Cyclosporine, Tobramycin and Vancomycin. Ocular delivery devices prepared by the methods may be used to treat a variety of eye disorders.Type: ApplicationFiled: November 22, 2013Publication date: July 3, 2014Applicants: Louisiana State University Agricultural and Mechanical College, ATON PHARMA, INC.Inventors: Jean Theresa JACOB, Kevin John HALLORAN, Yuri MCKEE
-
Publication number: 20140186514Abstract: Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties.Type: ApplicationFiled: December 23, 2013Publication date: July 3, 2014Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Muhammad Safadi, Daniella Licht, Rachel Cohen, Anton Frenkel, Marina Zholkovsky
-
Publication number: 20140178454Abstract: The present invention provides a coating comprising a reservoir layer comprising a semi-crystalline polymer and a primer layer comprising an amorphous polymer on an implantable device and methods of making and using the same.Type: ApplicationFiled: December 17, 2013Publication date: June 26, 2014Inventors: Florencia Lim, Mikael O. Trollsas, Syed F.A. Hossainy, Stephen D. Pacetti
-
Patent number: 8753708Abstract: A solventless method for forming a coating on a medical electrical lead is described. The method includes combining particles of a therapeutic agent with a polymeric material in a flowable form in the absence of a solvent to form a uniform suspension. A predetermined amount of the suspension is dispensed onto a portion of the lead and is then cured to form the therapeutic agent eluting layer. Additional layers such as a primer layer, fluoro-opaque layer and/or a topcoat layer can be formed using the solventless method. Employing a solventless method may avoid contraction of the layer being formed due to solvent evaporation during the curing process, and may facilitate greater control over the thickness of the therapeutic agent eluting coating.Type: GrantFiled: July 8, 2010Date of Patent: June 17, 2014Assignee: Cardiac Pacemakers, Inc.Inventors: Larry L. Hum, James Q. Feng, Arienne P. Simon, Tolga Tas
-
Publication number: 20140154328Abstract: The invention relates to an oral pharmaceutical composition comprising coated particles of a complex of at least one active agent with an ion-exchange resin, wherein said particles are coated with a bioadhesive coating layer comprising at least one bioadhesive material. The invention also relates to a process for preparing the oral pharmaceutical composition.Type: ApplicationFiled: April 5, 2012Publication date: June 5, 2014Inventor: Cvjetko Brkicic
-
Publication number: 20140154327Abstract: A microencapsulated enteric matrix composition and method for manufacture are provided. The microencapsulated enteric composition includes enteric material, such as sodium caseinate and soy protein, and a functional ingredient contained therein in a core. Further, the composition includes a first coating including zein and the second, outer coating including ethylcellulose. The microencapsulated enteric composition may be suitable for use in hot comestibles.Type: ApplicationFiled: December 3, 2012Publication date: June 5, 2014Inventors: Ahmad Akashe, Anilkumar Ganapati Gaonkar
-
Publication number: 20140127299Abstract: Disclosed herein are food-grade enteric coating compositions designed to release pharmaceutical and/or nutraceutical products at various regions of the intestines, wherein said compositions comprise a film former and a pore former. Also disclosed herein are methods of making and using same.Type: ApplicationFiled: November 7, 2013Publication date: May 8, 2014Inventor: Stephen Kwaku Dordunoo
-
Publication number: 20140127292Abstract: Oral pharmaceutical compositions for the controlled release of heparin or derivatives thereof, for example dalteparin, salts and/or derivatives thereof, comprising (a) a matrix consisting of amphiphilic compounds and lipophilic compounds with melting point lower than 90° C. in which the active ingredient is at least partially dispersed; (b) an outer hydrophilic matrix in which the lipophilic/amphiphilic matrix is dispersed; (c) optionally, other excipients suitable for solid pharmaceutical forms. The treatment of inflammatory bowel diseases (IBD) by administering to a patient in need thereof an effective amount of dalteparin, salts and/or derivatives thereof is also disclosed.Type: ApplicationFiled: December 30, 2013Publication date: May 8, 2014Applicant: Cosmo Technologies LimitedInventors: Mauro Ajani, Luigi Moro, Roberto Villa
-
Patent number: 8715728Abstract: An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient.Type: GrantFiled: December 3, 2009Date of Patent: May 6, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Thomas Friedl, Rolf-Stefan Brickl
-
Publication number: 20140112984Abstract: The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed.Type: ApplicationFiled: December 27, 2013Publication date: April 24, 2014Applicant: GRUENENTHAL GMBHInventors: Elisabeth ARKENAU-MARIC, Johannes BARTHOLOMÄUS, Heinrich KUGELMANN
-
Publication number: 20140114241Abstract: The present invention relates to a method for coating a surface of a substrate with a drug for sustained release: (i) providing a substrate with a surface to be coated, (ii) depositing at least one bilayer on at least a portion of said surface, wherein one layer of the bilayer comprises a polyelectrolyte and the other layer comprises a pharmaceutically active ingredient, and wherein the two layers of the bilayer are oppositely charged under conditions of the deposition and one layer of the bilayer has a substantially different net charge under physiological conditions. The invention also pertains to substrates with microscopic or macroscopic surfaces coated with the method according to the invention.Type: ApplicationFiled: June 1, 2011Publication date: April 24, 2014Applicant: CAPSULUTION PHARMA AGInventors: Andreas Voigt, Lutz Kröhne
-
Patent number: 8703210Abstract: A human consumable chemical compound of calcium carbonate which is coated with an impervious coating that will not allow the compound to dissolve from stomach acid but does allow it to dissolve in the aqueous environment of the intestine. The chemical compound is time released, and is positionally sensitive to reach the intestines of the human body where it is absorbed into the blood. Carbonic acid in the blood reacts upon the gradual dissolution of the compound and this reaction converts the calcium carbonate to calcium bicarbonate. Calcium bicarbonate in the blood neutralizes the body's harmful acidic wastes and is a substitute for drinking about fifty ounces of alkaline drinking water daily.Type: GrantFiled: August 10, 2005Date of Patent: April 22, 2014Assignee: Sang Lads, Inc.Inventor: Sang Y. Whang
-
Publication number: 20140107159Abstract: The present disclosure relates to compositions and methods for fabricating films for the delivery of a therapeutic agent containing at least one polymer and at least one therapeutic agent in a composition including a decreased alcohol fraction for providing smoother films and desired release characteristics. Drug-eluting films are also disclosed.Type: ApplicationFiled: September 17, 2013Publication date: April 17, 2014Applicant: Covidien LPInventors: Garrett Ebersole, Ryan Witherell, Amin Elachchabi, Joshua B. Stopek
-
Publication number: 20140105956Abstract: Novel sustained release biodegradable implants and methods of making and of using the same to treat ocular diseases are provided.Type: ApplicationFiled: October 11, 2013Publication date: April 17, 2014Inventors: Rupak BANERJEE, Soumyarwit MANNA, James AUGSBURGER
-
Publication number: 20140065232Abstract: An enteric-coated oral dosage form comprising an acid labile active pharmaceutical ingredient where the composition is substantially free of monomeric phthalic acid esters and synthetic oils is described herein. Also provided are methods for making and using the enteric-coated oral dosage form. The disclosed pharmaceutical compositions comprise an enteric coating which includes at least one plasticizer, at least one film-forming agent and optionally at least one anti-sticking agent.Type: ApplicationFiled: November 7, 2013Publication date: March 6, 2014Inventors: George Shlieout, Claus-Juergen Koelln, Frithjof Sczesny, Jens Onken, Andreas Koerner
-
Publication number: 20140056979Abstract: The present invention relates to pharmaceutical multilayer dosage forms, for example to a tamper resistant dosage form comprising a first layer comprising an active agent and a second layer not comprising said active agent, and processes of manufacture, uses, and methods of treatment thereof providing essentially zero order release.Type: ApplicationFiled: March 22, 2012Publication date: February 27, 2014Applicant: Purdue Pharma L.P.Inventor: Haiyong Hugh Huang
-
Publication number: 20140050797Abstract: The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical ingredient in at least one solubility-enhancing polymer, and a TPR coating comprising a water insoluble polymer and an enteric polymer, wherein the active pharmaceutical ingredient comprises a weakly basic active pharmaceutical ingredient having a solubility of not more than 100 ?g/mL at pH 6.8.Type: ApplicationFiled: June 6, 2013Publication date: February 20, 2014Inventors: Gopi VENKATESH, Luigi BOLTRI, Italo COLOMBO, Jin-Wang LAI, Flavio FABIANI, Luigi MAPELLI
-
Publication number: 20140044781Abstract: The present invention relates provides pharmaceutical compositions comprising an amorphous carvedilol salt and one or more pharmaceutically acceptable excipients, wherein the amorphous carvedilol salt is formed in situ during the preparation of the pharmaceutical composition. The amorphous carvedilol salt is preferably an amorphous carvedilol phosphate salt. The pharmaceutical compositions can be prepared by providing one or more inert cores; contacting the core or cores with a solution or a dispersion comprising carvedilol, an acid component and optionally a binder, in a solvent; removing the solvent; and optionally coating the core or cores with an extended release composition. Preferred pharmaceutical compositions contain both immediate-release pellets and at least one population of extended-release pellet.Type: ApplicationFiled: October 21, 2013Publication date: February 13, 2014Applicant: Amneal Pharmaceuticals, LLCInventors: Jatin Desai, Vipul Rasikbhai Gajjar, Gaurav Navinbhai Mistry, Parva Yogeshchandra Purohit
-
Publication number: 20140044860Abstract: Methods for increasing the fracture resistance of a polymer stent's drug-polymer coating and scaffolding including applying a coating and crimping using techniques that increase the resistance to fracture in the coating layer and scaffolding and scaffolding.Type: ApplicationFiled: October 15, 2013Publication date: February 13, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventors: Dan Castro, Yunbing Wang
-
Publication number: 20140023709Abstract: Oral tablet compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof having a gradual release and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders.Type: ApplicationFiled: September 23, 2013Publication date: January 23, 2014Applicant: SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETIInventors: Umit Cifter, Ali Turkyilmaz, Ibrahim Murat Uzer, Alper Terkinli, Levent Oner
-
Patent number: 8632844Abstract: A method for manufacturing a nerve regeneration-inducing tube with excellent pressure resistance, shape recovery property, anti-kink property, film exfoliation resistance, resistance to invasion of outer tissues, and leakage resistance. The tubular body is formed by weaving together fibers made up of biodegradable polymer. The outer surface of the tubular body is coated multiple times with a collagen solution. The lumen of the tubular body is filled with collagen. Viscosity of the collagen solution that is first applied to the outer surface of the tubular body is between 2 to 800 cps. Viscosity of the collagen solution that is subsequently applied is higher than viscosity of the first applied collagen solution.Type: GrantFiled: December 4, 2008Date of Patent: January 21, 2014Assignee: Toyo Boseki Kabushiki KaishaInventors: Fumihiko Kajii, Hidenori Tanaka, Yuta Kawakatsu, Susumu Kashiwabara, Masaki Sato
-
Publication number: 20140017324Abstract: An L-menthol-containing multiparticulate formulation includes a plurality of individual enteric coated cores containing L-menthol from an at least 80% pure L-menthol source. The enteric coated cores are effective to release at least about 35% of the L-menthol within about two hours, and at least about 80% of the L-menthol within about eight hours after being placed in an environment having a pH of 5 to 8. The L-menthol multiparticulate formulation can be used to treat gastrointestinal disorders.Type: ApplicationFiled: September 23, 2013Publication date: January 16, 2014Applicant: ZX PHARMA, LLCInventors: SYED SHAH, FRED HASSAN, DANIEL HASSAN, SARAH HASSAN
-
Publication number: 20140017310Abstract: The present disclosure provides pharmaceutical compositions comprising at least one active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, at least one hydrophilic plastomer, optionally at least one hydrophilic elastomer, and at least one deliquescent plasticizer, wherein the pharmaceutical compositions provide extended release of the API and have abuse deterrent properties. Also provided are methods for preparing the pharmaceutical compositions in which the components of the composition are humidified such that the deliquescent plasticizer deliquesces, thereby plasticizing the hydrophilic polymers.Type: ApplicationFiled: July 11, 2013Publication date: January 16, 2014Inventors: Brad L. Gower, Carlos H. Castaneda, Jae Han Park, Clifford J. Herman
-
Publication number: 20140004189Abstract: Modified release pharmaceutical compositions of memantine or pharmaceutically acceptable salts thereof are described. The compositions of invention are stable, possess improved formulation characteristics and also provide extended therapeutically effective plasma levels over a twenty four hours period. Processes of making these compositions are also described.Type: ApplicationFiled: January 25, 2012Publication date: January 2, 2014Applicant: CADILA HEALTHCARE LIMITEDInventors: Sunilendu Bhushan Roy, Sushrut Krishnaji Kulkarni, Sandhya Rajendra Shenoy, Imran Shakoor Ghogari, Vijaykumar Shivajrao Patil
-
Publication number: 20130344156Abstract: The invention provides microparticles for use in a pharmaceutical composition for pulmonary administration, each microparticle comprising a particle of an active substance having, on its surface, particles of a hydrophobic material suitable for delaying the dissolution of the active substance. The invention also provides a method for making the microparticles.Type: ApplicationFiled: March 27, 2013Publication date: December 26, 2013Applicant: VECTURA LIMITEDInventor: VECTURA LIMITED
-
Patent number: 8597716Abstract: Methods for increasing the fracture resistance of a polymer stent's drug-polymer coating and scaffolding including applying a coating and crimping using techniques that increase the resistance to fracture in the coating layer and scaffolding and scaffolding.Type: GrantFiled: June 23, 2009Date of Patent: December 3, 2013Assignee: Abbott Cardiovascular Systems Inc.Inventors: Dan Castro, Yunbing Wang
-
Publication number: 20130296439Abstract: A method of making a pharmaceutical composition containing tolterodine L-tartrate stabilized against degradation with an acid. Acid-stabilized tolterodine L-tartrate may be used as an active ingredient in various types of immediate release and controlled release dosage forms, including tablets, capsules, and beads.Type: ApplicationFiled: June 11, 2013Publication date: November 7, 2013Inventors: David T. Rossi, Boyong Li, James Paul McCall
-
Patent number: 8574659Abstract: A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube.Type: GrantFiled: January 15, 2010Date of Patent: November 5, 2013Assignee: pSivida US, Inc.Inventors: Hong Guo, Paul Ashton
-
Publication number: 20130280325Abstract: This invention relates to compressed solid oral dosage form able to contain a high load of active pharmaceutical ingredient, showing a controlled release profile, and consisting of individual particles wherein each individual particle comprises an active pharmaceutical ingredient and wherein each individual particle is coated with a layer comprising at least one plasticizer.Type: ApplicationFiled: December 22, 2011Publication date: October 24, 2013Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.Inventors: Luis Soler Ranzani, Albert Falivene Aldea, Ángel Santanach Delisau, Gemma Casadevall Pujals
-
Patent number: 8562669Abstract: The present invention relates to methods of applying a drug—polymer coating layer onto an implantable medical device or another substrate, and the use of a choice of solvents to adjust the release of the drug from the coating. The drug to polymer ratio is about 1:1 to 1:3 on a mass basis. The polymer and the drug are hydrophobic.Type: GrantFiled: June 26, 2008Date of Patent: October 22, 2013Assignee: Abbott Cardiovascular Systems Inc.Inventors: Stephen D. Pacetti, Gordon S. Stewart, Victoria M. Gong, Chandana Bellam, Lisa M. Weldon
-
Publication number: 20130266721Abstract: A process for the preparation of controlled drug release porous hydroxyapatite microspheres, in the form of granules, consisting of interconnected pore channels with high porosity. It comprises the steps of mixing nano-hydroxyapatite powder with camphene to form a homogenous mixture followed by mixing said homogenous mixture with gelatin solution to form a complex mixture. This complex mixture is dispersed in cold stirring oil in a beaker until said dispersed granules hardens to form green bodies. These green bodies are subjected to heat treatment to obtain porous hydroxyapatite microspheres, subjecting the said porous hydroxyapatite microspheres to antibiotics encapsulation.Type: ApplicationFiled: April 6, 2012Publication date: October 10, 2013Inventor: Tapash Ranjan Rautray
-
Publication number: 20130266658Abstract: The present invention relates to a method of producing a pharmaceutical preparation that contains a proton pump inhibitor and optionally a non-steroidal anti-inflammatory drug in the form of pellets. The invention further relates to pharmaceutical preparations obtainable by said method, in particular those with a defined dissolution profile.Type: ApplicationFiled: May 29, 2013Publication date: October 10, 2013Inventors: Gerd Weiß, Thomas Profitlich, Karl Schwitzer, Cornelia Wagner, Manfred Schwitzer, Bernhard Huber
-
Publication number: 20130260015Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: ApplicationFiled: May 23, 2013Publication date: October 3, 2013Applicant: Purdue Pharma L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Publication number: 20130245549Abstract: Bioactive agents are embedded in a cross-linked dextran and coated with a bioresorbable polymer. When implanted in a mammal, the coated cross-linked dextran composition produces controlled release of the embedded bioactive agent.Type: ApplicationFiled: September 12, 2012Publication date: September 19, 2013Applicant: ROYER BIOMEDICAL, INC.Inventors: Garfield P. ROYER, Tatiana Bizikova
-
Publication number: 20130209554Abstract: A gelatin capsule composition that includes one or more first distinct regions comprising a gelatin and one or more second distinct regions comprising a water-insoluble rapid-release agent is provided.Type: ApplicationFiled: June 29, 2012Publication date: August 15, 2013Applicant: GelitaInventors: Tom Keenan, John M. Dolphin
-
Publication number: 20130209553Abstract: The present invention discloses an extended release pharmaceutical composition of pramipexole or salts thereof comprising at least 40% w/w of hydrogenated castor oil, and one or more pharmaceutically acceptable excipients.Type: ApplicationFiled: April 15, 2011Publication date: August 15, 2013Applicant: CADILA HEALTHCARE LIMITEDInventors: Sunilendu Bhushan Roy, Sushrut Krishnaji Kulkarni, Ajay Kumar Handa, Pranav Dhirajbhai Jogani
-
Publication number: 20130202710Abstract: Composition for the prolonged release of trimetazidine wherein the inner phase comprises trimetazidine and the outer layer comprises a retardant and an anti-agglomerant.Type: ApplicationFiled: January 29, 2013Publication date: August 8, 2013Applicant: LES LABORATOIRES SERVIERInventor: LES LABORATOIRES SERVIER
-
Patent number: 8501226Abstract: The present invention concerns a method for coating granules comprising mesalazine, with a coating mixture comprising two polymers, polymer I and polymer II; said polymer I being selected to allow formation of a closing membrane around said granules in the absence of said polymer II, and said polymer II being selected to act as a water-soluble pore former in said coating mixture; wherein a) the amount of polymer I is adjusted to provide a closing membrane in the absence of polymer II, and b) the amount of polymer II in said coating mixture is adjusted to obtain coated granules which exhibit controlled release of mesalazine. The invention further concerns a product obtainable by the coating method.Type: GrantFiled: September 7, 2012Date of Patent: August 6, 2013Assignee: Ferring B.V.Inventors: Svenn Klüver Jepsen, Gudrun Lasskogen
-
Patent number: 8496954Abstract: Described are coating systems for the controlled delivery of hydrophilic bioactive agents, for example, from implantable medical devices. The coating systems of the invention comprise (a) a polymeric basecoat layer containing one or more hydrophilic bioactive agents; and (b) an elution-controlling topcoat layer that comprises a poly(ethylene-co-vinyl acetate) copolymer. The elution rate of the hydrophilic bioactive agent can be controlled by varying the vinyl acetate concentration in the elution-controlling topcoat layer.Type: GrantFiled: April 17, 2009Date of Patent: July 30, 2013Assignee: Surmodics, Inc.Inventors: Ralph A. Chappa, Robert W. Hergenrother, Shannon A. Wadman, Klaus R. Wormuth
-
Patent number: 8496964Abstract: The present invention relates to a microcapsule for controlled release of flavanoid compound and a process for preparation thereof. The microcapsule comprising a core particle consisting of a calcium salt, Pluronic F68 [poly (ethylene oxide-co-polypropylene oxide), block poly oxyethylene-polypropylene block copolymer], loaded with a flavanoid compound, the resulting core particle having a plurality of alternate layers of cationic and anionic polyelectrolytes adsorbed thereon and an outer layer formed by a bile salt, wherein the flavanoid is ranging between 10 to 96% by weight.Type: GrantFiled: February 26, 2010Date of Patent: July 30, 2013Assignee: Council of Scientific & Industrial ResearchInventors: Prabhat Ranjan Mishra, Ritu Trivedi, Girish Kumar Gupta, Avinash Kumar, Varsha Gupta, Srikanta Kumar Rath, Kamini Srivastava, Naibedya Chattopadhyay, Anil Kumar Dwivedi
-
Publication number: 20130183434Abstract: The invention provides a method for preparing a mesalazine enteric coated tablet comprising: (i) granulating a composition comprising mesalazine, a pharmaceutically acceptable salt, or ester thereof, into mesalazine granulates; (ii) tabletting a core composition comprising the mesalazine granulates obtained in (i) to obtain a tablet core; (iii) coating the tablet core obtained in (ii) with at least an intermediate layer and an enteric coating; where the tablet core hardness is controlled to be comprised between 80 N and 105 N and the intermediate layer represents less than 2% by weight of the tablet.Type: ApplicationFiled: September 1, 2011Publication date: July 18, 2013Applicant: DISPHAR INTERNATIONAL B.V.Inventor: Hendrik Cornelis De Fluiter
-
Publication number: 20130178492Abstract: The present invention relates to prolonged release pharmaceutical dosage forms, the manufacture thereof as well as their use for administration to human beings.Type: ApplicationFiled: May 10, 2011Publication date: July 11, 2013Applicant: Euro-Celtique S.A.Inventors: Helen Kathleen Danagher, Hassan Mohammad, Malcolm Walden, Geoffrey Gerard Hayes, Jonathon Oliver Whitehouse, Thinnayam Naganathan Krishnamurthy, Ricardo Alberto Vargas Rincon